91 studies found for:    topeka | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Vaginal Cancer
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
22 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Solid Neoplasm;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
23 Recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
24 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
25 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
26 Recruiting Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Conditions: Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
27 Recruiting S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
28 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
29 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
30 Recruiting Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: CP-690,550
31 Recruiting Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: other disease-modifying therapy
32 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
33 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
34 Recruiting Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
Condition: Septic Shock
Interventions: Drug: selepressin;   Drug: placebo
35 Recruiting TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
Condition: Pneumonia
Interventions: Drug: TR-701 FA IV;   Drug: Linezolid
36 Recruiting Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
Condition: Nosocomial Pneumonia
Interventions: Drug: ceftolozane/tazobactam;   Drug: Meropenem
37 Recruiting Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
Condition: Crohn's Disease
Interventions: Drug: CROWN;   Drug: CROWN Placebo
38 Recruiting A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)
Condition: Ulcerative Colitis
Interventions: Drug: Adalimumab;   Other: Adalimumab Placebo;   Drug: Etrolizumab;   Other: Etrolizumab Placebo
39 Recruiting A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Condition: Type 2 Diabetes
Interventions: Drug: Dulaglutide;   Drug: Placebo
40 Recruiting Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide;   Drug: liraglutide;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.